1. The complex spectrum of neurodegenerative diseases {#s0010}
=====================================================

Epidemiologic data indicate that neurodegenerative diseases (NDDs) show high prevalence with a trend of a progressively growing incidence, especially in aging societies. This presents an increasing social and economic burden. In individuals \>60 years of age, the prevalence of Alzheimer\'s disease (AD) is estimated to be 40 of 1000 persons with an annual incidence of 34 per 1000 persons.[@bib0010] Parkinson\'s disease (PD) is considered the second most common NDD after AD,[@bib0015] and, similarly to AD, its prevalence consistently increases with age.

The pathologic term *neurodegeneration* refers to a heterogeneous group of progressively evolving central nervous system (CNS) and brain diseases. It is an "umbrella" term indicating gradual structural neuronal loss with functional consequences due to the abnormal accumulation of misfolded and dysfunctional proteins within the complex nervous system. Therefore, NDDs are better classified as protein misfolding disorders or proteinopathies of the CNS and the brain. For consistency reasons, however, we will use the traditional term of NDDs throughout this perspective.

NDDs may be either monogenic (i.e., characterized by mutations) like Huntington disease, with more-or-less monolinear mechanistic pathophysiology, or complex polygenic (e.g., sporadic late-onset AD), that is, involving several pathophysiological and nonlinear progressive biological mechanisms.[@bib0020] Lifestyle, environmental risk factors, and variability of individual genetic polymorphisms contribute to the onset and progression of the idiopathic and polygenic forms of NDDs. In this perspective, we focus on the complex multifactorial NDDs that are most relevant and represent the major clinical phenotypes, including cognitive impairment and dementia in the general aging population.

Among emerging theories, it has been postulated that a specific misfolded protein characteristic of the pathobiochemistry in a particular NDD can spread from one cell to another (both transcellularly and synaptically) in a prion-like manner, thus potentially inducing complex neural network alterations, which are structural and functional system substrates of clinical symptomatic progression at advanced stages of NDDs.[@bib0025], [@bib0030] Notably, these aberrantly altered proteins represent candidate targets for therapy development and/or may be utilized as specific diagnostic and prognostic biomarkers of disease. The neurodegenerative process is hypothesized to initiate focally and then propagate strategically across wider brain regions through complex networks, in line with specific dynamic progression patterns likely defined by genetic drivers and triggers during the initiation stages of the proteinopathy.[@bib0025], [@bib0035] Hence, as a consequence, the emerging pathophysiological mechanisms, the subsequent neuropathology, and both the time of onset and dynamics of progression through time and space and the emergence of the late-stage clinical phenotype of NDDs can vary substantially between postulated clinical disease groups, subsets of disease, and individuals grouped into those operationalized categories. For instance, "typical AD"---that is, the hippocampal variant of AD according to the International Working Group-2 diagnostic criteria[@bib0040]---shows, at the preclinical asymptomatic stage, a marked alteration and subsequent disruption of the default mode network,[@bib0035] whereas primaryprogressive aphasia displays a pattern of network dysfunction mainly localized in language brain areas.[@bib0025] However, several cases of amyloid beta (Aβ) pathophysiology may also exhibit atypical patterns of network change leading to disconnection and disintegration.[@bib0040] The atypical variants---namely, frontal, posterior, and logopenic---present behavioral, visual, or language symptoms, which from a clinical point of view overlap those involved in other NDDs. These include behavioral frontotemporal dementia (FTD), generally categorized as a tauopathy; dementia with Lewy bodies (DLB), which is linked to synucleinopathies; and primary progressive aphasia, classified as transactive-response DNA-binding protein 43 proteinopathy or, alternatively, as a tauopathy. As a result, distinct proteinopathies may induce different patterns of early functional and anatomic alteration of brain networks in NDDs. Moreover, it remains unclear how misfolded proteins are translating into distinct patterns of complex network impairment over longer periods of years and decades and, ultimately, result in very different clinical motor and/or cognitive syndromes.

2. An outdated vision {#s0015}
=====================

On this basis of an inherent genetic and biological heterogeneity, determination of an early and accurate diagnosis of NDDs merely from descriptive clinical symptoms and syndromes is most challenging and questionable. In the past 30 years, international diagnostic consensus criteria for diagnosing NDDs in the clinical setting scenario have been formulated more or less slowly, refined and updated to ameliorate the phenotypical characterization of disease categories associated and compared with final postmortem pathologic examination. However, in spite of intense efforts, the clinical criteria for diagnosing NDDs still remain largely variable in terms of delineation between categories and their subsets, diagnostic and classificatory accuracy, and clinical practicality.[@bib0040], [@bib0045], [@bib0050], [@bib0055], [@bib0060], [@bib0065], [@bib0070] Postmortem neuropathologic studies confirm that the clinical diagnostic criteria of PD are very good, in terms of both sensitivity (90%) and specificity (around 100%), at distinguishing PD from other forms of Parkinsonism, provided that they are assessed in expert centers highly specialized in the diagnosis of movement disorders.[@bib0055] For AD, the neuropathologic "gold standards"[@bib0075] have shown that purely clinical diagnostic criteria[@bib0080] exhibit correlative accuracy in terms of sensitivity (81%) and specificity (70%), mostly in specialist settings. The clinical diagnostic criteria for other NDDs exhibit high specificity but low sensitivity; in this respect, the clinical diagnostic criteria for DLB have very good specificity (95%) but poor sensitivity (around 30%),[@bib0085] although according to the third report of the DLB Consortium,[@bib0070], [@bib0085] the sensitivity has recently improved. Similarly, the criteria for progressive supranuclear palsy display a specificity of 100% and a sensitivity of 50%.[@bib0065] Moreover, pathologic examination[@bib0050] has shown that the accuracy of the clinical diagnostic criteria for corticobasal degeneration, a rare form of atypical Parkinsonism, is unsatisfactory. This applies to the clinical diagnostic criteria of FTD[@bib0060] as well; indeed, as opposed to a specific disease category, FTD is considered a disease spectrum in itself clinically characterized by progressive behavioral, executive, and language impairment, encompassing symptoms typical of motor neuron diseases (i.e., amyotrophic lateral sclerosis), and Parkinsonism.[@bib0090] Notably, the overlapping impact of cerebrovascular alterations in neurodegenerative processes should also be carefully considered in the clinicopathologic interpretation of any NDDs.[@bib0095] In conclusion, in most cases, a classification system based purely on a clinical descriptive diagnosis is largely heterogeneous, practically highly unreliable, and not very helpful as a basis of therapy development across the NDD spectrum. The traditional clinicopathologic diagnosis scheme is largely unable to specifically consider the diverse genetic underpinnings and multiple pathophysiological mechanisms underlying the complex dimensional spectrum of NDDs.

Given the substantial discrepancies commonly found between clinical and pathologic diagnoses, the idea of an existing biunivocal relationship between a definite clinical phenotype and its corresponding neuropathology appears misleading and unrealistic. In addition, proteinopathies may largely appear in combination with effects associated with brain aging and cerebrovascular disease, thus arranging a complex multidimensional and not categorical clinicopathologic *continuum* exhibiting mixed patterns of partly converging neurodegenerative mechanisms with overlapping and converging comorbidities.[@bib0020], [@bib0040], [@bib0045]

Currently, based on the pathologic deposition of misfolded proteins in the CNS, NDDs may be categorized as follows: cerebral amyloidosis (AD), tauopathies (progressive supranuclear palsy, corticobasal degeneration, behavioral variant of FTD, progressive nonfluent aphasia of FTD), synucleinopathies (PD, DLB, multiple system atrophy), and transactive response DNA-binding protein 43 proteinopathies (semantic variant of FTD, behavioral FTD, amyotrophic lateral sclerosis).[@bib0030]

However, postmortem neuropathologic examination frequently reveals the deposition of multiple misfolded proteins, reflecting a mixed pattern of proteinopathies in an examined patient. DLB and PD with dementia often present overlapping Aβ-related pathology. Several studies have reported the accumulation of α-synuclein within Lewy body inclusions in the brains of AD patients.[@bib0045] In addition, minor strokes, small vessel disease, and cerebral amyloid angiopathy, alone or in combination, are associated with high prevalence of progressive neurodegeneration, thus making it additionally challenging to precisely label and dissect any pathologic categorization.[@bib0095] In this regard, a community-based neuropathologic study has reported a consistent variability in the expression of several combinations of multiple proteinopathies within the CNS of elderly subjects. This demonstrates that the coexistence of mixed neuropathologies is commonly observed in the clinical setting[@bib0100] and increasingly during aging.

3. Forward an adaptive perspective {#s0020}
==================================

In view of this, the way forward is to expand the scope of detection and diagnosis in defining biological criteria of NDDs, as in other disease fields. Discovery, development, and validation of distinct biological/pathophysiological biomarkers and genetic drivers/triggers of NDDs is the key to step up progress of *in vivo* diagnostic, prognostic, and therapeutic (biomarker-guided therapy) technologies. In particular, (1) postmortem examination is not sufficient or practical for early detection and diagnosis purposes; (2) postmortem examination represents not an early dynamic *in vivo* assessment but rather a late-stage result of visible traces of several pathophysiological mechanisms potentially leading to different dynamics of onset and progression; (3) asymptomatic and cognitively healthy elderly subjects are likely to display postmortem neuropathologic deposits of misfolded protein; (4) multiple misfolded deposits of proteins detected within the CNS may coexist in the same clinical phenotype or in the same patient; (5) a clinical phenotype may exhibit more than 1 aberrant process of protein deposition; and (6) a general agreement on the definition of pathologic vascular processes and dementia is still missing.[@bib0045], [@bib0095]

To overcome stagnation in effective early disease detection and drug development for NDDs, a paradigm shift is evolving from clinically and clinicopathologic descriptive phenotypes to clinicobiological definitions, toward the ultimate solutions of a true "precision medicine".

The precision medicine paradigm aims at targeting the issue of genetic, molecular, and clinical heterogeneity by identifying a person\'s comprehensive and specific pattern of risk, reflected by polygenetic as well as epigenetic[@bib0105] variants, such as high-to-medium risk mutations, structural, functional, and metabolic imaging indicators, and fluid biomarkers, then detecting and delineating the array of molecular pathophysiological mechanisms underlying disease processes and finally administering a preventive or therapeutic intervention that is specific (i.e., "tailored or customized") to the identified molecular pattern and biological disease progression pattern in time and space. This paradigm is clearly in contrast with the traditional idea that NDDs are homogeneous clinicopathologic and clinicobiological entities and can be treated with the resulting, largely inadequate "one-drug-fits-all" approach.[@bib0110] Notably, the scientifically advanced, more matured translational research fields of oncology or rheumatology have already begun the implementation and practical use of precision medicine and could serve as an inspirational model for neuroscience, neurology, and psychiatry. This approach is promising breakthroughs in the future of medicine, including the almost isolated and detached field of complex psychiatric disorders.[@bib0110] Thanks to the emergence of systems theory and the complex neural network paradigm, the implementation of large-scale biological databases, and the development of high-throughput screening methods---the "-omic" tools---which can aid in characterizing disease biomarkers, precision medicine is likely to be practically applied broadly across a vast number of human diseases. Such an integrative and interdisciplinary approach is possible through the maturing field of systems biology.[@bib0115]

Translating innovative concepts from theory to practice is undoubtedly challenging, especially in the multifaceted and still largely unexplored field of neurologic and psychiatric brain diseases. In summary, we need an innovative, practical model allowing patient stratification in a way that is pertinent to clinical trials. To this end, for patients showing cognitive impairment supposedly associated with a proteinopathy or neurodegeneration, we propose a practical diagnostic approach structured on 3 different assessment levels: (1) traditional, clinical descriptive; (2) transitional, both clinical and biomarker based; and (3) an unbiased biomarker-guided *a posteriori* aggregation scheme. Our initial aim will be to compare the 3 levels of stratification to overcome traditional reductionistic and obsolete classification models. The first level will be based on a purely clinical diagnostic categorization, in which we will study the diagnostic accuracy of core biomarkers (i.e., Aβ~1--42~, p-tau, t-tau) as well as novel emerging candidate biomarkers in discriminating between *a priori* defined clinical groups (for instance, typical AD dementia patients *vs.* probable DLB (dementia stage) patients). The second level will encompass a combined clinical- and a biomarker-driven diagnostic approach. In detail, we will test the performance of the array of emerging and novel candidate biomarkers to differentiate subgroups of patients within the dementia and mild cognitive impairment categories as well as in asymptomatic subjects stratified according to the unbiased descriptive "A/T/N" system for characterizing the AD spectrum, recently proposed by Jack and colleagues.[@bib0120] In brief, this unbiased classification scheme---theoretically appropriate for any NDD---is based on 3 binary biomarker categories that reflect the core pathophysiological mechanisms of AD: in particular, "A" refers to Aβ pathology, "T" to hyperphosphorilated tau (p-tau) pathology, and "N" to total tau (t-tau) or other biomarkers of neurodegeneration.[@bib0120] In the third level of analysis, we will preserve the conceptual distinction of the severity of cognitive impairment by identifying 3 "macroclinical" categories of subjects/patients: (1) asymptomatic subjects, (2) prodromal or mild cognitive impairment subjects, and (3) syndromic demented patients. Successively, within these categorical diagnostic macrogroups, we will employ advanced machine learning techniques to define novel patient subsets in an unbiased *a posteriori* clustering process based on a combination of genetic polymorphisms, blood- and cerebrospinal fluid (CSF)-based fluid biomarkers, and multimodal neuroimaging data. We will focus on unsupervised pattern recognition methods with the objective of detecting higher-order, nonlinear associations within the multidimensional data point represented by each patient in the highly heterogeneous space constituted by genetic, imaging, and biohumoral data. This will result in novel innovative, unbiased categorizations based on effective degrees of freedom present in a subject\'s enlarged biomarker panel, hence independent of the large variance clinical phenotypes, and these degrees of freedom will define and span the effective dimensions of the biological continuum of NDDs. In turn, this could form the basis for formulating mechanistic (rather than purely data-driven) integrative models, with the goal of explaining disease endophenotypes and phenotypes in an individualized fashion.[@bib0125] The parameters estimated by these models could aid in early detection, diagnosis, and prognosis and eventually function as so-called *preventive biomarkers* (i.e., aid in stratifying the population into risk classes).[@bib0125] As a final result of this articulated process, a set of optimal cutoffs and, hence, an unbiased descriptive panel displaying a sequence of categorizations for NDDs may be developed ([Fig. 1](#f0010){ref-type="fig"}).Fig. 1Unbiased descriptive classification system of neurodegenerative dementia integrating clinical and biomarker information. Level I indicates the severity of symptomatic impairment ranging from asymptomatic to dementia. Level II indicates differentiated neuropsychological characterization. Level III indicates the evolving array of topographical and pathophysiological biomarkers. Level IV indicates additional neurologic signs and symptoms useful for categorization, such as extrapyramidal signs, cerebellar ataxia, *etc.* \* Evolving array of validated pathophysiological and topographic biomarkers (genetic, biochemical, neuroimaging). A = Aβ amyloid; MCI = mild cognitive impairment; N = t-tau; S = α-synuclein; SCI = subjective cognitive impairment; T = p-tau; V = vascular.Fig. 1

During the past decade, conceptual shifts have occurred in the field of NDDs, and these diseases are now considered as partly overlapping, dynamic, nonlinear progressive "dimensions" that reside among a wide spectrum of brain proteinopathies. Future breakthrough discoveries are likely to happen through transfertilization from more advanced research fields, such as oncology, by means of the innovative precision medicine and systems biology paradigms. This reintegration of neuroscience and neurology into biological medicine will be characterized by advancing biomarker research objectively reflecting the multifaceted pathophysiological profile of sporadic and polygenic NDDs. This will allow the characterization and identification of disease even at the earliest asymptomatic preclinical stage through population-based screening efforts facilitated by the Precision Medicine Initiative. In this context, given that early biomarker-guided intervention may offer the best chance of therapeutic success, the preclinical stage of AD and other NDDs has become a major research focus. To date, very little evidence has been established on this uncharted "silent stage".[@bib0130] A clarification is needed about the definitions and lexicon, the limits, the natural history, the markers of risk and progression, and the ethical consequence of detecting the disease at this asymptomatic stage and how to effectively operationalize precision medicine.
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